Tetra Radar · FDA Approvals · Decision date
Biomarin Pharmaceutical Inc: FDA decision date
Biomarin Pharmaceutical Inc (BMRN) · 30 May 2027
Food and Drug Administration (FDA) set a Prescription Drug User Fee Act (PDUFA) target action date of May 30, 2027 for supplemental new drug application (sNDA) to expand the use of VOXZOGO for the treatment of hypochondroplasia (HCH).
Source: 10-Q of 3 November 2026
The decision is pending.
Biomarin Pharmaceutical Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.